Form 4: Jazz Pharmaceuticals CEO Bruce Cozadd Disposes of Shares to Cover Tax Obligations
SEC Form 4
Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals, disposed of 22,251 ordinary shares to satisfy tax obligations arising from the vesting of restricted stock units.
Summary
- On March 5, 2025, Bruce C Cozadd, Chairman and CEO of Jazz Pharmaceuticals plc, disposed of 22,251 ordinary shares.
- The shares were sold at a price of $138.95 per share.
- The transaction was executed to cover tax obligations related to the vesting of previously granted restricted stock units.
- Following the transaction, Cozadd directly owns 441,807 ordinary shares.
Sentiment
Score: 6
Explanation: Neutral sentiment as the transaction is a routine sale of shares to cover tax obligations, not necessarily indicative of the company's performance or future prospects.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies, often related to compensation and tax planning. The sale itself doesn't necessarily indicate a negative outlook for the company, as it's often a routine part of executive financial management.
Stakeholder Impact
- The transaction is unlikely to have a significant impact on shareholders, as it is a routine sale of shares by an executive for tax purposes.
Key Dates
| Date | Description |
|---|---|
| 03/05/2025 | Date of transaction: Disposal of shares |
| 03/07/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.